Corcept Therapeutics (NASDAQ: CORT) puts resistant hypertension in the cortisol spotlight with new MOMENTUM trial data
Incyte (NASDAQ: INCY) moves closer to an hidradenitis suppurativa launch as 54-week povorcitinib data hold up
Read More Pharma Industry News Kardigan’s tonlamarsen data put acute severe hypertension into sharper commercial focus Kardigan’s tonlamarsen Phase 2 data showed blood pressure promise despite mixed endpoints. Read what it means for acute severe hypertension next. byVenkateshMarch 29, 2026